CCL

Összesen 6 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM038689
035-os BibID:PMID:15301236
Első szerző:Bodolay Edit (belgyógyász, allergológus és klinikai immunológus)
Cím:Anti-endothelial cell antibodies in mixed connective tissue disease : frequency and association with clinical symptoms / E. Bodolay, I. Csipő, I. Gál, S. Sipka, E. Gyimesi, Z. Szekanecz, G. Szegedi
Dátum:2004
Megjegyzések:AbstractOBJECTIVE: Anti-endothelial cell antibodies (AECA) have been described in a number of systemic autoimmune-inflammatory diseases. However, little is known about the relationship of AECA with mixed connective tissue disease (MCTD).METHODS: Using an ELISA, the presence of AECA was evaluated in the sera of 33 patients with MCTD and of 30 healthy subjects as controls. Serum levels of AECA were correlated with clinical activity, as well as the existence of various organ manifestations.RESULTS: Significantly increased AECA production was observed in MCTD patients (OD = 0.337+/-0.193) compared to controls (OD = 0.136+/-0.065). In addition, patients with active MCTD exerted significantly elevated serum AECA levels (OD = 0.487+/-0.090) than did patients with inactive MCTD (OD = 0.135+/-0.040) or controls. MCTD patients with pulmonary hypertension had a tendency of increased serum AECA levels (OD = 0.452+/-0.080) compared to patients without this manifestation (OD = 0.307+/-0.039). Sera of MCTD patients with AECA concentrations higher or lower than the mean serum AECA level in controls+2SD (OD = 0.266) were considered as AECAhigh (n = 19/33) and AECAlow (n = 14/33), respectively. Interestingly, all patients with active disease had AECAhigh, while all inactive MCTD patients had AECAlow sera. IgG purified from ten MCTD sera (OD = 0.415+/-0.290) showed a tendency to up-regulate E-selectin expression on cultured human umbilical vein endothelial cells (HUVEC) compared to IgG from control sera. In addition, AECAhigh MCTD sera exerted significantly increased stimulatory effect on endothelial E-selectin expression (OD = 0.651+/-0.190) compared to AECAlow (OD = 0.178+/-0.110) or control sera (OD = 0. 131+/-0.080).CONCLUSION: AECA may activate endothelial cells by the up-regulation of E-selectin expression and thus may be implicated in the pathogenesis of MCTD. Furthermore, serum AECA may be a useful marker of endothelial activation and clinical activity in this disease.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
anti-endothelial antibodies
mixed connective tissue disease
symptoms
Adult
Autoantibodies
Cells, Cultured
Dose-Response Relationship, Immunologic
E-Selectin
Endothelial Cells
Endothelium, Vascular
Enzyme-Linked Immunosorbent Assay
Female
Humans
Hypertension, Pulmonary
Immunoglobulin G
Male
Middle Aged
Mixed Connective Tissue Disease
egyetemen (Magyarországon) készült közlemény
Megjelenés:Clinican and Experimental Rheumatology. - 22 : 4 (2004), p. 409-415. -
További szerzők:Csípő István (1953-) (vegyész) Gál I. Sipka Sándor (1945-) (laboratóriumi szakorvos) Gyimesi Edit (1957-) (klinikai biokémikus, vegyész) Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Szegedi Gyula (1936-2013) (belgyógyász, immunológus)
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
Borító:

2.

001-es BibID:BIBFORM007050
Első szerző:Bodolay Edit (belgyógyász, allergológus és klinikai immunológus)
Cím:Five-year follow-up of 665 Hungarian patients with undifferentiated connective tissue disease (UCTD) / Bodolay, E., Csiki, Z., Szekanecz, Z., Ben, T., Kiss, E., Zeher, M., Szucs, G., Danko, K., Szegedi, G.
Dátum:2003
ISSN:0392-856X (Print)
Megjegyzések:To determine the clinical symptoms and the panel of autoantibodies of patients with early undifferentiated connective tissue disease (UCTD) followed for at least 1 year. METHODS: 716 UCTD patients with manifestations suggestive but not diagnostic of specific connective tissue disease (CTD) were recruited and followed up between 1994-1999. The patients with early UCTD were subdivided into those with isolated Raynaud's phenomenon (RP) (50 patients), unexplained polyarthritis (31 patients) and "true" UCTD (665 patients). UCTD was diagnosed on the basis of clinical manifestations suggestive of a connective tissue disease and the presence of at least one non-organ specific autoantibody. The patients' sera were tested for anti-nuclear (ANA), as well as for nine different specific autoantibodies (anti-dsDNA, -Sm, -RNP, -SSA, -SSB, -Scl-70, -centromere, -Jo1 and -PM-Scl). RESULTS: The most common clinical manifestations of UCTD included RP, arthritis/arthralgias, pleuritis/pericarditis, sicca symptoms, cutaneous involvement (photosensitivity, rash), central nervous symptoms, peripheral neuropathy, fever, vasculitis, less pulmonary involvement and myositis. 230 of the 665 true UCTD patients (34.5%) developed a defined CTD (28 systemic lupus erythematosus [SLE], 26 mixed connective tissue disease [MCTD], 19 progressive systemic sclerosis [PSS], 45 Sjogren's syndrome, 3 polymyositis/dermatomyositis [PM/DM], 87 rheumatoid arthritis [RA], and 22 systemic vasculitis. 435 of 665 patients (65.4%) remained in the UCTD state, and 82 of 665 patients (12.3%) achieved complete remission with symptoms not reappearing within the 5-year period. The highest probability of evolution to a defined CTD was during the first 2 years after onset: of 230 UCTD patients 183 (79.5%) developed major organ symptoms and signs. In particular skin and cardiac complications seemed to spread during the follow-up period in those patients who progressed to SLE. The condition of 18/50 patients with isolated RP evolved to UCTD and 3 of 31 patients with unexplained polyarthritis progressed to definite CTD (2 patients RA and one MCTD). CONCLUSION: In our study most of the UCTD patients did not develop a definite CTD, but during the follow-up period we found new clinical and serological manifestations. One-third of the UCTD patients showed progress into different types of specific CTD.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Adolescent
Adult
Aged
Autoantibodies
Autoimmunity
Cohort Studies
Confidence Intervals
Connective Tissue Diseases
Disease Progression
Female
Follow-Up Studies
Humans
Hungary
Logistic Models
Lupus Erythematosus, Systemic
Male
Middle Aged
Polymyositis
Probability
Prognosis
Retrospective Studies
Scleroderma, Systemic
egyetemen (Magyarországon) készült közlemény
Severity of Illness Index
Sjogren's Syndrome
Time Factors
Vasculitis
Megjelenés:Clinical and Experimental Rheumatology. - 21 : 3 (2003), p. 313-320. -
További szerzők:Csiki Zoltán (1962-) (belgyógyász, allergológus, klinikai immunológus, reumatológus) Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Ben, Thomas Kiss Emese (1960-) (belgyógyász, immunológus) Zeher Margit (1957-2018) (belgyógyász, allergológus és klinikai immunológus, reumatológus) Szűcs Gabriella (1963-) (belgyógyász, allergológus és klinikai immunológus, reumatológus) Dankó Katalin (1952-2021) (belgyógyász, allergológus és klinikai immunológus) Szegedi Gyula (1936-2013) (belgyógyász, immunológus)
Internet cím:elektronikus változat
Borító:

3.

001-es BibID:BIBFORM089545
035-os BibID:(WOS)000600601200003 (Scopus)85097310520
Első szerző:Burmester, Gerd R.
Cím:Evolving the comprehensive management of rheumatoid arthritis : identification of unmet needs and development of practical and educational tools / G. R. Burmester, J. M. Álvaro-Gracia, N. Betteridge, J. Calvo Alén, B. Combe, P. Durez, B. Fautrel, R. J. O. Ferreira, C. Gabay, A. Iagnocco, C. Montecucco, M. štergaard, S. Ramiro, A. Rubbert-Roth, T. Stamm, Z. Szekanecz, P. C. Taylor, M. van de Laar
Dátum:2020
ISSN:0392-856X
Megjegyzések:Objectives: Despite availability of efficacious treatments, unmet needs still exist, preventing optimal and comprehensive management of rheumatoid arthritis (RA). Evolving the management of RA (eRA) is a European-wide educational initiative aiming to support improved patient care through practical and educational tools addressing specific unmet needs. Methods: A multidisciplinary Steering Committee (17 members, 12 countries) identified unmet needs within the management of RA and prioritised those with the greatest impact on patient outcomes. Practical educational tools addressing priority needs were then developed for dissemination and implementation by the rheumatology community across Europe. Results: Five areas of priority need were identified: increasing early recognition of RA and treatment initiation; treating RA to target; optimal, holistic approach to selection of treatment strategy, including shared decision-making; improving identification and management of comorbidities; and non-pharmacological patient management. A suite of 14 eRA tools included educational slides, best-practice guidance, self?assessment questionnaires, clinical checklists, a multidisciplinary team training exercise, an interactive patient infographic, and case scenarios. By April 2020, rheumatology professionals in 17 countries had been actively engaged in the eRA programme; in 11 countries, eRA tools were selected by national leaders in rheumatology and translated for local dissemination. A web platform, with country-specific pages, was developed to support access to the translated tools (https://www.evolvingthemanagementofra.com/). Conclusions: The eRA programme supports comprehensive management of RA across Europe through development and dissemination of practical educational tools. The eRA tools address priority needs and are available free of charge to the rheumatology community.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Rheumatoid arthritis
medical education
delivery of health care
rheumatology
patient care team
Megjelenés:Clinical And Experimental Rheumatology. - 38 (2020), p. 1056-1067. -
További szerzők:Álvaro-Gracia, Jose María Betteridge, Neil Calvo Alén, Jaime Combe, Bernard Durez, Patrick Fautrel, Bruno Ferreira, Ricardo J. O. Gabay, Cem Iagnocco, Annamaria Montecucco, Carlo Maurizio štergaard, Mikkel Ramiro, Sofia Rubbert-Roth, Andrea Stamm, Tanja A. Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Taylor, Peter C. van de Laar, Mart
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
Borító:

4.

001-es BibID:BIBFORM015934
Első szerző:Csípő István (vegyész)
Cím:Decreased serum tryptophan and elevated neopterin levels in systemic sclerosis / Csipo I., Czirjak L., Szanto S., Szerafin L., Sipka S., Szegedi G.
Dátum:1995
ISSN:0392-856X (Print)
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Adult
Aged
Biopterin/*analogs & derivatives/blood
Humans
Immunity, Cellular
Middle Aged
Neopterin
Scleroderma, Systemic/*blood/immunology
Tryptophan/*blood
Megjelenés:Clinical and experimental rheumatology. - 13 : 2 (1995), p. 269-270. -
További szerzők:Czirják László Szántó Sándor (1968-) (belgyógyász, reumatológus) Szerafin László (1958-) (belgyógyászat, haematológia, klinikai onkológia szakorvos) Sipka Sándor (1945-) (laboratóriumi szakorvos) Szegedi Gyula (1936-2013) (belgyógyász, immunológus)
Internet cím:elektronikus változat
Borító:

5.

001-es BibID:BIBFORM006925
Első szerző:Lakos Gabriella (laboratóriumi szakorvos, transzfúziológus, immunológus)
Cím:Anti-cyclic citrullinated peptide antibody isotypes in rheumatoid arthritis : association with disease duration, rheumatoid factor production and the presence of shared epitope / Lakos Gabriella, Soós Lilla, Fekete Andrea, Szabó Zoltán, Zeher Margit, Horváth Ildikó Fanny, Dankó Katalin, Kapitány Anikó, Gyetvai Ágnes, Szegedi Gyula, Szekanecz Zoltán
Dátum:2008
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Clinical and Experimental Rheumatology. - 26 : 2 (2008), p. 253-260. -
További szerzők:Soós Lilla Fekete Andrea (immunológus) Szabó Zoltán (1970-) (belgyógyász, reumatológus) Zeher Margit (1957-2018) (belgyógyász, allergológus és klinikai immunológus, reumatológus) Horváth Ildikó Fanny (1980-) (belgyógyász, allergológus, klinikai immunológus) Dankó Katalin (1952-2021) (belgyógyász, allergológus és klinikai immunológus) Kapitány Anikó (1979-) (molekuláris biológus) Gyetvai Ágnes Szegedi Gyula (1936-2013) (belgyógyász, immunológus) Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus)
Internet cím:elektronikus változat
elektronikus változat
Borító:

6.

001-es BibID:BIBFORM081583
035-os BibID:(WOS)000531365800016 (Scopus)85075957157
Első szerző:Szekanecz Zoltán (reumatológus, belgyógyász, immunológus)
Cím:Cigarette smoking and clinical response to certolizumab pegol treatment in Hungarian, Czech, and Slovak patients with rheumatoid arthritis : 104-week data from the CIMDORA prospective, non-interventional study / Z. Szekanecz, Á. Koncz, J. Dunkel, J. Vencovský, CIMDORA collaborators
Dátum:2019
Megjegyzések:Objective Smoking has been shown to influence rheumatoid arthritis (RA) severity and reduce response to some anti-tumour necrosis factor (anti-TNF) therapies. CIMDORA assessed the association between cigarette smoking and clinical effectiveness of certolizumab pegol (CZP) in Hungarian, Slovak, and Czech RA patients. Methods CIMDORA was a prospective, non-interventional, 104-week study (Feb 2011?Aug 2015). The primary endpoint was association between change in 28-joint Disease Activity Score (DAS28[ESR]) from baseline to Week 12, and baseline cigarette pack-year history. Secondary endpoints included association between change in DAS28(ESR) and daily number of cigarettes smoked. The full analysis set (FAS) included all patients receiving ?1 dose of CZP with all necessary assessments for the primary endpoint. Treatment-emergent adverse events (TEAEs) were reported for all patients receiving ?1 dose of CZP. Results The FAS included 218/273 enrolled patients: 155 Hungarian, 46 Czech and 17 Slovak. Hungarian and Czech patients completed 104 weeks (n=141); Slovak patients completed 52 weeks. Mean change in DAS28(ESR) [SD] at Week 12 (-2.78 [1.47]) was not significantly associated with baseline cigarette pack-year history (slope estimate [SE]: 0.03, 95% confidence interval [CI]: -0.16, 0.21 [p=0.77]). Mean DAS28(ESR) [SD] reductions to Week 52 (-3.33 [1.33]) were not significantly associated with daily number of cigarettes smoked in the previous month (SE: 0.001, CI: -0.05, 0.05 [p=0.95]). Two deaths were reported but neither of them was related to CZP. No new safety signals were identified and the safety profile was consistent with previous CZP studies. Conclusion After 104 weeks of CZP treatment, patients demonstrated similar DAS28(ESR) improvements, irrespective of smoking history.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
rheumatoid arthritis
cigarette smoking
anti-rheumatic agents
tumour necrosis factor-alpha
Megjelenés:Clinical and Experimental Rheumatology. - 37 : 6 (2019), p. 1010-1018. -
További szerzők:Koncz Ágnes Dunkel, J. Vencovsky, Jiri CIMDORA collaborators
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Rekordok letöltése1